2015
DOI: 10.1158/1078-0432.ccr-14-1559
|View full text |Cite
|
Sign up to set email alerts
|

Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

Abstract: Purpose: Preparative lymphodepletion, the temporal ablation of the immune system, has been reported to promote persistence of transferred cells along with increased rates of tumor regression in patients treated with adoptive T-cell therapy. However, it remains unclear whether lymphodepletion is indispensable for immunotherapy with T-cell receptor (TCR) gene-engineered T cells.Experimental Design: We conducted a first-in-man clinical trial of TCR gene-transduced T-cell transfer in patients with recurrent MAGE-A… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
92
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 145 publications
(102 citation statements)
references
References 39 publications
2
92
0
Order By: Relevance
“…The transduced T cells were detectable in peripheral blood for approximately 2 months in 7/10 patients, and retained ex vivo reactivity to MAGE-A4. The tumor responses were mixed, but with minimal toxicity, this study demonstrates the feasibility of the approach (37).…”
Section: Adoptive Cell Transfer Therapies In Gej Cancermentioning
confidence: 67%
“…The transduced T cells were detectable in peripheral blood for approximately 2 months in 7/10 patients, and retained ex vivo reactivity to MAGE-A4. The tumor responses were mixed, but with minimal toxicity, this study demonstrates the feasibility of the approach (37).…”
Section: Adoptive Cell Transfer Therapies In Gej Cancermentioning
confidence: 67%
“…Clinical trials of immunotherapeutic targets for CT antigens have been actively performed. NY-ESO-1, MAGEA3 and MAGEA4 are of particular interest to researchers and clinicians, and developments in immunotherapeutic techniques including peptide vaccines, dendritic cell vaccines and T cell receptor gene transduced T lymphocytes for these CT antigens are currently underway (33)(34)(35).…”
Section: Discussionmentioning
confidence: 99%
“…Although clinical benefit has been demonstrated, the reported toxicity is non-depreciable [28,29]. TCR gene transduced T-cell transfers in patients with recurrent MAGE-A4-expressing ESCC have shown preliminary clinical benefit [30]. Thus, a number of trials are investigating these therapies (NCT01967823, NCT02366546, NCT02111850, NCT02096614, NCT01174121).…”
Section: Adoptive T-cell Therapymentioning
confidence: 99%